Parkinson disease
Summary
Definition
History and exam
Key diagnostic factors
- bradykinesia
- resting tremor
- rigidity
- postural instability
Other diagnostic factors
- masked facies
- hypophonia
- hypokinetic dysarthria
- micrographia
- stooped posture
- shuffling gait
- conjugate gaze disorders
- fatigue
- constipation
- depression
- anxiety
- dementia
- exposure to antipsychotics or antiemetics
- features of atypical parkinsonism
- hyposmia/anosmia
- sleep disorders
Risk factors
- increasing age
- history of familial PD in younger-onset disease
- mutation in gene encoding glucocerebrosidase
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure
- chronic exposure to metals
- male sex
- additional genetic risk factors
- head trauma
- geographic influence
- toxin exposure
- occupation
Diagnostic tests
1st tests to order
- dopaminergic agent trial
Tests to consider
- MRI brain
- functional neuroimaging (dopamine transporter imaging such as FP-CIT or beta-CIT SPECT, or fluorodopa PET)
- olfactory testing
- genetic testing
- neuropsychometric testing
- serum ceruloplasmin
- 24-hour urine copper
- cardiac sympathetic innervation using iodine-123 meta-iodobenzylguanidine (MIBG)
- brain pathology (postmortem)
Emerging tests
- skin biopsy
Treatment algorithm
mild parkinsonism
moderate parkinsonism
advanced parkinsonism
Contributors
Authors
Delaram Safarpour, MD, MSCE
Assistant Professor of Neurology
Department of Neurology
School of Medicine
Oregon Health & Science University
Portland
OR
Declarações
DS has received honoraria for participation in advisory boards for Boston Scientific (the manufacturer of Deep Brain Stimulation device) and Abbvie (the manufacturer of Duopa). She has received consultation fees from Abbott (the manufacturer of Deep Brain Stimulation device). DS has received an institutional grant and has received an honorarium for lectures from Parkinson Study Group.
Marian L. Dale, MD, MCR
Assistant Professor of Neurology
Department of Neurology
Oregon Health & Science University
Staff Neurologist
Portland VA Medical Center
Portland
OR
Declarações
MLD has received consulting honoraria from Synergic Medical Technologies and UCB, and has received grant funding from the NIH and the Collins Medical Trust.
Lauren S. Talman, MD
Assistant Professor of Neurology
Department of Neurology
School of Medicine
Oregon Health & Science University
Portland
OR
Declarações
LST declares that she has no competing interests.
Agradecimentos
Dr Delaram Safarpour, Dr Marian L. Dale, and Dr Lauren S. Talman would like to gratefully acknowledge Dr Avram Fraint, Dr Danny Bega, Dr Meredith Spindler, Dr Jayne R. Wilkinson, and Dr Andrew D. Siderowf, the previous contributors to this topic.
Declarações
DB served on the speaker's bureau for Teva Pharmaceuticals, and ACADIA Pharmaceutical, Inc; he has received consultancy fees from US WorldMeds and grant support from the Parkinson Foundation; he was on the board of directors for Rock Steady Boxing Windy City. AF, MS, JRW, and ADS declare that they have no competing interests.
Revisores
Graham A. Glass, MD
Assistant Clinical Professor
Department of Neurology
UCSF Medical Center
Parkinson's Disease Research
Education and Clinical Center
San Francisco
CA
Declarações
GAG declares that he has no competing interests.
Daniel Kremens, MD, JD
Assistant Professor of Neurology
Jefferson Medical College
Thomas Jefferson University
Philadelphia
PA
Declarações
DK declares that he has no competing interests.
Donald Grosset, BSc (Honours), MB, ChB, MD, FRCP
Consultant Neurologist / Honorary Senior Lecturer
Institute of Neurological Sciences
Southern General Hospital / University of Glasgow
Glasgow
UK
Declarações
DG is an author of a reference cited in this topic.
Patricia Dowsey Limousin, MD, PhD
Reader in Clinical Neurology
Honorary Consultant
Institute of Neurology
National Hospital for Neurology and Neurosurgery
London
UK
Divulgaciones
PDL declares that she has no competing interests.
Nikolaus McFarland, MD, PhD
Assistant Professor
Department of Neurology
University of Florida College of Medicine
Gainesville
FL
Divulgaciones
NM declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. Resumen
Internation Parkinson and Movement Disorder Society. MDS position paper: diagnosis of Parkinson's disease. Mar 2023 [internet publication].Texto completo
Pringsheim T, Day GS, Smith DB, et al; Guideline Subcommittee of the AAN. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-57.Texto completo Resumen
Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease - an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-98.Texto completo Resumen
Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-66.Texto completo Resumen
Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson's disease: executive summary. Neurosurgery. 2018 Jun 1;82(6):753-6.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Essential tremor
- Progressive supranuclear palsy (PSP)
- Multiple system atrophy (MSA; MSA-A, formerly Shy-Drager syndrome; MSA-P, striatonigral degeneration; MSA-C, olivopontocerebellar atrophy)
Más DiferencialesGuías de práctica clínica
- ACR–ACNM–SNMMI practice parameter for the performance of dopamine transporter (DaT) single photon emission computed tomography (SPECT) imaging for movement disorders
- European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies
Más Guías de práctica clínicaFolletos para el paciente
Parkinson disease: what is it?
Parkinson disease: what are the treatment options?
Más Folletos para el pacienteVideos
Parkinson disease neurological assessment
Más vídeos
Inicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad